Deloitte: Global Economic Downturn Likely to Change Face of Life Sciences
R&D, biotech hit hard; innovation crucial for companies to get ahead
New York, May 5, 2010 — Curbing costs in response to the global economic downturn, as well as the continuing capital crunch, is likely to have a long-term impact on the life sciences industries, according to a new white paper released by Deloitte Touche Tohmatsu Limited (Deloitte). Developed in collaboration with The Economist Intelligence Unit, the Deloitte white paper, entitled, “The Future of Life Sciences Industries: Aftermath of the global recession,” is based on an online survey of 281 senior industry executives during Fall 2009. The report sought to assess the short- and long-term impact of the global recession on the life sciences industries.
Nearly one-third of the executives surveyed see a reduction of R&D spend in the future, and nearly half believe that up to 40 percent of biotech companies will cease to exist in five years.
But while the recession has caused companies to downsize R&D—with 43 percent of respondents focusing on products that would provide a more immediate return and 32 percent reducing R&D spend—a full 30 percent say that developing a robust R&D pipeline and focusing on innovation are important to their longer-term success.
Existing challenges intensified
“While the immediate hit of the recession has been largely absorbed, the life sciences industry may look back at this time as a turning point,” said Robert Go, Deloitte Touche Tohmatsu Limited Global Life Sciences and Health Care Industry Leader. “Health plans driving out costs, expiring patents, evolving generics legislation—all of these trends were in play before the economic downturn, but the downturn is now accelerating their impact.”
The report points to a variety of trends and challenges intensified by the downturn that may leave the life sciences industry permanently changed:
The end of biotech as we know it?
While the near-collapse of the global capital markets had immediate implications for even the largest competitors in the industry—with many moves to consolidate now on hold—the impact on biotech may be staggering. Sixty-eight percent of biotech executives surveyed believe that between 20 and 40 percent of biotech companies won’t exist in five years as a result of the global economic downturn. In addition, nearly one-third of respondents predict an outflow of scientists from smaller to larger companies.
It also seems that the lines between biotech and pharmaceuticals will become further blurred as major pharmaceutical players use their stronger capital position to expand more aggressively into large molecule research. And even when capital markets recover, investors burned by the downturn may have a more guarded perception of risk and return.
“With the dearth of new entrepreneurial entries, the talent flight, and the encroachment of large pharma, the future for biotech looks grim,” said Reynold W. (Pete) Mooney, Deloitte Touche Tohmatsu Limited Global Life Sciences and Health Care Consulting Leader. “And the big, longer-term impact may be a shifting of the industry’s ‘balance of innovation,’ with a shift that now favors the large, well-capitalized enterprises.”
Survey respondent demographics
Of the 281 executives responding to the 2009 survey, 33 percent are from Western Europe; 26 percent are from North America; 28 percent are from Asia-Pacific; and the remainder is from the Middle East, Africa, and Latin America. Forty-six percent of respondents work for companies with global annual revenue exceeding US$500 million. Respondents all hail from the life sciences industries, led by pharmaceuticals at 30 percent (R&D, manufacturing, or wholesale distribution), medical devices (16 percent), biotechnology (14 percent), and contract research organizations (6 percent). The remainder is from health care services, distribution, and health insurance. Of the respondents, 133 are board members or C-level executives.
To read the full report, visit www.deloitte.com/lifesciencessurvey.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.
Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 140 countries, Deloitte brings world-class capabilities and deep local expertise to help clients succeed wherever they operate. Deloitte's approximately 170,000 professionals are committed to becoming the standard of excellence.